Track topics on Twitter Track topics that are important to you
RATIONALE: GDC-0449 and RO4929097 may slow the growth of tumor cells and may be an effective treatment for advanced breast cancer.
- To determine the safety and tolerability of Hedgehog antagonist GDC-0449 in combination with gamma-secretase inhibitor RO4929097 in women with advanced breast cancer.
- To determine the dose-limiting toxicity and maximum tolerated dose and/or recommended phase II dose of this regimen in these patients.
- To determine the pharmacokinetics and pharmacogenetics of Hedgehog antagonist GDC-0449 and gamma-secretase inhibitor RO4929097 when administered alone and in combination.
- To attempt to evaluate select pharmacodynamic stem cell differentiation biomarkers in the Hedgehog and Notch signaling pathways (e.g., Gli1/2/3, Ptch1/2, Hes1, Hip1, Hey1, Notch4, Jagged1, Numb, Bmi-1, CD44/CD24, ALDH) and the percentage of breast cancer stem cells in serial breast tumor biopsies before and after Hedgehog antagonist GDC-0449 or gamma-secretase inhibitor RO4929097 when administered alone and after 1 course of treatment when administered in combination.
- To determine tumor response in patients with measurable disease as assessed by RECIST criteria.
OUTLINE: This is a multicenter study.
Patients receive oral gamma-secretase inhibitor RO4929097 on day 1 OR on days -2, -1, and 1 and oral Hedgehog antagonist GDC-0449 on days 8-21 of course 1. Beginning in course 2, patients receive oral gamma-secretase inhibitor RO4929097 on days 1-3 and 8-10 and oral Hedgehog antagonist GDC-0449 on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Blood, tumor tissue, and hair samples are collected periodically for pharmacokinetic, pharmacodynamic, pharmacogenomic, and other correlative biomarker studies.
After completion of study treatment, patients are followed up for 30 days.
Masking: Open Label, Primary Purpose: Treatment
Hedgehog antagonist GDC-0449, gamma-secretase inhibitor RO4929097, laboratory biomarker analysis, pharmacogenomic studies, pharmacological study
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Cancer Institute (NCI)
Published on BioPortfolio: 2014-08-27T03:15:48-0400
RATIONALE: Enzyme inhibitors, such as gamma-secretase inhibitor RO4929097, may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I...
RATIONALE: Gamma-secretase inhibitor RO4929097 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine hy...
This randomized phase I/II clinical trial is studying the side effects and best dose of gamma-secretase/notch signalling pathway inhibitor RO4929097 when given together with vismodegib and...
RATIONALE: Gamma-secretase inhibitor RO4929097 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I/II clinical trial is study...
RATIONALE: Gamma-secretase inhibitor RO4929097 and cediranib maleate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Cediranib maleate also may s...
Desmoid fibromatosis is a fibroblastic neoplasm driven by aberrations within the WNT pathway, exhibiting mutations in β-catenin or APC. We review the long-term follow-up of patients in a phase I stud...
Aberrant reactivation of the Sonic Hedgehog (SHH) signaling pathway promotes prostate cancer (PC) growth and progression by regulating cancer-related genes through its downstream effectors GLI1 and GL...
Vismodegib (also known as GDC-0449) is a novel small molecule inhibitor of the Hedgehog (Hh) signaling pathway currently approved for the treatment of metastatic or locally advanced basal cell carcino...
The Notch pathway is frequently activated in cancer. Pathway inhibition by γ-secretase inhibitors has been shown to be effective in pre-clinical models of pancreatic cancer, in combination with gemci...
How to effectively delivering therapeutic agents, including γ-secretase inhibitors (GSIs), into live cells, remains a significant challenge. This study assessed the effect of Notch signaling inhibiti...
An inhibitor of glutamate decarboxylase and an antagonist of GAMMA-AMINOBUTYRIC ACID. It is used to induce convulsions in experimental animals.
A frizzled-like, G-protein-coupled receptor that associates with PATCHED RECEPTORS to transduce signals from HEDGEHOG PROTEINS and initiate hedgehog signaling to ZINC FINGER PROTEIN GLI1. It may normally inhibit signaling in the absence of SONIC HEDGEHOG PROTEIN binding to PATCHED RECEPTOR-1.
A family of intercellular signaling proteins that play and important role in regulating the development of many TISSUES and organs. Their name derives from the observation of a hedgehog-like appearance in DROSOPHILA embryos with genetic mutations that block their action.
Integral membrane protein of Golgi and endoplasmic reticulum. Its homodimer is an essential component of the gamma-secretase complex that catalyzes the cleavage of membrane proteins such as NOTCH RECEPTORS and AMYLOID BETA-PROTEIN precursors. PSEN2 mutations cause ALZHEIMER DISEASE type 4.
Integral membrane proteins and essential components of the gamma-secretase complex that catalyzes the cleavage of membrane proteins such as NOTCH RECEPTORS and AMYLOID BETA-PROTEIN precursors. Mutations of presenilins lead to presenile ALZHEIMER DISEASE with onset before age 65 years.
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...
Track and monitor developments in breast cancer research and commercial development. Follow the tabs above to read the latest global news, research, clinical trials on breast cancer and follow companies active in the development of breast cancer tr...